General Information of Drug (ID: DMMWC6F)

Drug Name
INCB9471 Drug Info
Synonyms
INCB-9471; UNII-C5D4W25708; INCB9471; CHEMBL1688243; INCB009471; C5D4W25708; INCB-009471; INCB 9471; INCB0 09471; 869769-98-2; SCHEMBL3676335; ZINC43171152; BDBM50339033; DB12960; 925701-76-4; Piperidine, 1-((4,6-dimethyl-5-pyrimidinyl)carbonyl)-4-((3S)-4-((1R,2R)-2-ethoxy-2,3-dihydro-5-(trifluoromethyl)-1H-inden-1-yl)-3-methyl-1-piperazinyl)-4-methyl-; 5-((4-(4-(2-Ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl)-4-methylpiperidin-1-yl)carbonyl)-4,6-dimethylpyrimidine
Indication
Disease Entry ICD 11 Status REF
Infectious disease 1A00-CA43.1 Phase 2a [1]
Human immunodeficiency virus infection 1C62 Phase 2 [2]
Cross-matching ID
PubChem CID
49871007
CAS Number
CAS 869769-98-2
TTD Drug ID
DMMWC6F

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Maraviroc DMTL94F Human immunodeficiency virus infection 1C62 Approved [4]
Vicriviroc DMMTW9K Human immunodeficiency virus infection 1C62 Phase 3 [5]
PRO-140 DMD1FTP Human immunodeficiency virus infection 1C62 Phase 3 [6]
E-913 DMUHS5Q Human immunodeficiency virus infection 1C62 Phase 3 [3]
PRO 140 DMCGK6X Human immunodeficiency virus-1 infection 1C62 Phase 2/3 [7]
Cenicriviroc DM4V8WF Human immunodeficiency virus infection 1C62 Phase 2 [8]
BMS-813160 DMKY638 Diabetic nephropathy GB61.Z Phase 2 [9]
SB-728-T DMRWE5D Human immunodeficiency virus infection 1C62 Phase 2 [10]
PF-232798 DM8T6KQ Human immunodeficiency virus infection 1C62 Phase 2 [11]
GSK-706769 DMPLKAH Human immunodeficiency virus infection 1C62 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 5 (CCR5) TT2CEJG CCR5_HUMAN Antagonist [3]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023697)
2 Clinical pipeline report, company report or official report of Incyte.
3 Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
4 Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
5 HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42.
6 Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62.
7 The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353.
8 The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6.
9 A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
10 Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910.
11 An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.
12 Tapping into combination pills for HIV. Nat Rev Drug Discov. 2009 Jun;8(6):439-40.